{
      "brief_title": [
            "safety",
            "interferon",
            "rituximab",
            "lymphoma",
            "patient"
      ],
      "brief_summary": [
            "evaluate",
            "safety",
            "efficacy",
            "dose",
            "schedule",
            "subcutaneous",
            "interferon",
            "ifn",
            "administer",
            "3",
            "time",
            "per",
            "week",
            "rituximab",
            "4",
            "week",
            "patient",
            "progressive",
            "relapse",
            "lymphoma",
            "nhl",
            "international",
            "study",
            "sit",
            "czech",
            "republic",
            "poland"
      ],
      "condition": [
            "lymphoma"
      ],
      "intervention_type": [
            "drug"
      ],
      "intervention_name": [
            "rituximab"
      ],
      "description": [
            "375",
            "mg",
            "per",
            "square",
            "meter",
            "iv",
            "per",
            "week"
      ],
      "criteria": [
            "relapse",
            "progressive",
            "nhl",
            "candidate",
            "rituximab",
            "therapy",
            "patient",
            "therapy",
            "include",
            "chop",
            "radiation",
            "previous",
            "therapy",
            "must",
            "conclude",
            "30",
            "day",
            "prior",
            "enrollment",
            "demonstrable",
            "tumor",
            "population",
            "lymph",
            "nod",
            "bone",
            "marrow"
      ],
      "gender": [],
      "minimum_age": [
            "18",
            "year"
      ],
      "maximum_age": [
            "80",
            "year"
      ],
      "healthy_volunteers": false,
      "id": "NCT00057447.xml"
}